239 related articles for article (PubMed ID: 14615744)
1. Successful use of anti-CD20 (rituximab) in severe, life-threatening childhood immune thrombocytopenic purpura.
Bengtson KL; Skinner MA; Ware RE
J Pediatr; 2003 Nov; 143(5):670-3. PubMed ID: 14615744
[TBL] [Abstract][Full Text] [Related]
2. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
Braendstrup P; Bjerrum OW; Nielsen OJ; Jensen BA; Clausen NT; Hansen PB; Andersen I; Schmidt K; Andersen TM; Peterslund NA; Birgens HS; Plesner T; Pedersen BB; Hasselbalch HC
Am J Hematol; 2005 Apr; 78(4):275-80. PubMed ID: 15795920
[TBL] [Abstract][Full Text] [Related]
3. Rituximab: a new therapeutic tool for primary immune thrombocytopenic purpura?
Introna M; Golay J; Barbui T
Haematologica; 2003 May; 88(5):482-4. PubMed ID: 12745265
[No Abstract] [Full Text] [Related]
4. Successful treatment of refractory immune thrombocytopenia with anti-CD20 antibody in a patient with systemic lupus erythematosus.
Lee JW; Kim HA; Sung JM; Suh CH
Lupus; 2010 Feb; 19(2):227-8. PubMed ID: 19884220
[No Abstract] [Full Text] [Related]
5. Rituximab: an anti-CD20 antibody for the treatment of chronic refractory immune thrombocytopenic purpura.
Aggarwal A; Catlett JP
South Med J; 2002 Oct; 95(10):1209-12. PubMed ID: 12425512
[TBL] [Abstract][Full Text] [Related]
6. Rituximab treatment for chronic refractory idiopathic thrombocytopenic purpura.
Zhou Z; Yang R
Crit Rev Oncol Hematol; 2008 Jan; 65(1):21-31. PubMed ID: 17681784
[TBL] [Abstract][Full Text] [Related]
7. Rituximab in the treatment of relapsing idiopathic thrombocytopenic purpura.
Riksen NP; Keuning JJ; Vreugdenhil G
Neth J Med; 2003 Jul; 61(7):262-5. PubMed ID: 14567524
[TBL] [Abstract][Full Text] [Related]
8. Chronic refractory idiopathic thrombocytopenic purpura (ITP) and anti-CD20 monoclonal antibody: a case report.
Latifzadeh SZ; Entezari V
Clin Appl Thromb Hemost; 2006 Oct; 12(4):489-92. PubMed ID: 17000895
[TBL] [Abstract][Full Text] [Related]
9. Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases.
Koulova L; Alexandrescu D; Dutcher JP; O'Boyle KP; Eapen S; Wiernik PH
Am J Hematol; 2005 Jan; 78(1):49-54. PubMed ID: 15609292
[TBL] [Abstract][Full Text] [Related]
10. Refractory autoimmune thrombocytopenic purpura: responses to treatment with a recombinant antibody to lymphocyte membrane antigen CD20 (rituximab).
Narang M; Penner JA; Williams D
Am J Hematol; 2003 Dec; 74(4):263-7. PubMed ID: 14635207
[TBL] [Abstract][Full Text] [Related]
11. Rituximab for the treatment of childhood chronic idiopathic thrombocytopenic purpura and hemophilia with inhibitors.
Franchini M; Zaffanello M; Veneri D; Lippi G
Pediatr Blood Cancer; 2007 Jul; 49(1):6-10. PubMed ID: 17311349
[TBL] [Abstract][Full Text] [Related]
12. A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia.
Saleh MN; Gutheil J; Moore M; Bunch PW; Butler J; Kunkel L; Grillo-López AJ; LoBuglio AF
Semin Oncol; 2000 Dec; 27(6 Suppl 12):99-103. PubMed ID: 11226008
[TBL] [Abstract][Full Text] [Related]
13. Clinical remission following monoclonal anti-CD20 therapy in two children with chronic refractory idiopathic thrombocytopenic purpura.
Moschovi M; Trimis G; Pergantou H; Platokouki H; Vrachnou E; Tzortzatou-Stathopoulou F
J Paediatr Child Health; 2005 Jul; 41(7):384-6. PubMed ID: 16014149
[TBL] [Abstract][Full Text] [Related]
14. Anti-CD20 monoclonal antibody (rituximab) for refractory autoimmune thrombocytopenia in a girl with systemic lupus erythematosus.
ten Cate R; Smiers FJ; Bredius RG; Lankester AC; van Suijlekom-Smit LW; Huizinga TW; Egeler RM
Rheumatology (Oxford); 2004 Feb; 43(2):244. PubMed ID: 14739467
[No Abstract] [Full Text] [Related]
15. Should rituximab be used before or after splenectomy in patients with immune thrombocytopenic purpura?
Cooper N; Evangelista ML; Amadori S; Stasi R
Curr Opin Hematol; 2007 Nov; 14(6):642-6. PubMed ID: 17898569
[TBL] [Abstract][Full Text] [Related]
16. [Effective treatment with rituximab in a patient with refractory idiopathic thrombocytopenic purpura].
Tanai C; Iki S; Nakahara F; Iijima K; Usuki K; Kuwana M; Urabe A
Rinsho Ketsueki; 2004 Nov; 45(11):1181-6. PubMed ID: 15609684
[TBL] [Abstract][Full Text] [Related]
17. B-cell compartment as the selective target for the treatment of immune thrombocytopenias.
Zaja F; Vianelli N; Sperotto A; De Vita S; Iacona I; Zaccaria A; Masolini P; Tomadini V; Tani M; Molinari AL; Baccarani M; Fanin R
Haematologica; 2003 May; 88(5):538-46. PubMed ID: 12745273
[TBL] [Abstract][Full Text] [Related]
18. Response of refractory immune thrombocytopenic purpura in a patient with common variable immunodeficiency to treatment with rituximab.
El-Shanawany TM; Williams PE; Jolles S
J Clin Pathol; 2007 Jun; 60(6):715-6. PubMed ID: 17483248
[No Abstract] [Full Text] [Related]
19. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura.
Cooper N; Stasi R; Cunningham-Rundles S; Feuerstein MA; Leonard JP; Amadori S; Bussel JB
Br J Haematol; 2004 Apr; 125(2):232-9. PubMed ID: 15059147
[TBL] [Abstract][Full Text] [Related]
20. Effect of a single dose of rituximab in chronic immune thrombocytopenic purpura in childhood.
Taube T; Schmid H; Reinhard H; von Stackelberg A; Overberg US
Haematologica; 2005 Feb; 90(2):281-3. PubMed ID: 15710595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
